Devonyu/iStock via Getty Images Shares of nano-cap diagnostics company Virax Biolabs Group ( NASDAQ: VRAX ) more than doubled in value in the morning hours Thursday as the company drew Wall Street's attention amid a rising number of bird flu cases worldwide. Several countries, including the U.S.
, have already reported human bird flu infections as the highly pathogenic avian influenza virus, including its H5N1 form, continues to spread in poultry and cattle. On Wednesday, the World Health Organization (WHO) confirmed the death of a 59-year-old linked to bird flu in Mexico, marking the first laboratory-confirmed human case of infection with the H5N2 strain of the virus. In March 2023, Virax ( VRAX ) launched its avian influenza A virus real-time PCR test kit in the European Union for laboratory use.
The test can detect and differentiate H5, H7, and H9 subtypes, including the H5N1 strain of the virus, the U.K.-based firm said at the time.
More on Virax Biolabs Financial information for Virax Biolabs Group Limited.
